As my colleague Jolie O’Dell said, it’s a “vibrating buttplug that makes you poop?”

Vibrant Conducts Pilot Trial with Vibrating Capsule for Chronic Constipated Patients

Petach Tikva, Israel, September 11, 2012. Vibrant Ltd. today announced that it is conducting a pilot trial of the company’s anti-constipation vibrating capsule. The clinical trial is taking place at two Israeli hospitals among patients with chronic idiopathic constipationFirst results of the trial will be reported at the 20th United European Gastroenterology Week, to be held in Amsterdam, The Netherlands, October 20-24, 2012.

“First indications show signs of positive impact and we are awaiting the trial’s completion,” said Dr. Laurent Choppe, Managing Partner at Cukierman & Co. Life Sciences.

The mechanically operated capsule is a breakthrough treatment for constipated patients. It meets the highest safety standards and uses biocompatible materials.

“By using no chemicals, Vibrant’s treatment concept is a novel approach for people who suffer from constipation. Market need consists of about 8-10% of the world’s population,” said Lior Ben-Tsur, Vibrant Chief Executive Officer.

Vibrant is currently raising funds from private investors to complete a financing round that will enable the company to complete a multi-center clinical study and prepare for market launch.

Vibrant constipation relief technology is based on the effect of the capsule’s vibrations on the wall of the large intestine, consequently inducing peristaltic activity and generating spontaneous additional bowel movement. The easy-to-swallow capsule is controlled through algorithms, predefined by Vibrant R&D and gastroenterology advisers.

The capsule is activated by a base unit that transfers the predefined algorithm’s data into the capsule, before it is swallowed. The capsule operates inside the large intestine and is washed out of the body with the bowel movement, leaving no chemicals in the body.

The company plans to complete the pivotal clinical trial by mid-2013 and obtain CE mark.